Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | PHGDH | O43175 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897142 | 0.89 | POLB (0.72) | POLBKMT2AALDH1A1LMNAGSK3B | |
| Hydrochloric Acid SCHEMBL7930353 | 0.85 | ALDH1A1 (0.67) | KMT2AMAPTALDH1A1KCNJ1LMNA | |
| SCHEMBL4875447 | 0.84 | POLB (0.82) | POLBTDP1MAPTALDH1A1LMNA | |
| SCHEMBL11023598 | 0.83 | KMT2A (0.60) | POLBKMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL298658 | 0.82 | GSK3B (0.73) | POLBKMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL27580337 | 0.82 | POLB (0.60) | POLBKMT2ATDP1MAPTALDH1A1 | |
| SCHEMBL932621 | 0.80 | ATM (0.57) | KMT2AMAPTALDH1A1LMNAGSK3B | |
| SCHEMBL287513 | 0.79 | KCNJ1 (0.73) | POLBKCNJ1HRH3 | |
| Hydrochloric Acid SCHEMBL8842385 | 0.79 | ALDH1A1 (0.62) | KMT2ATDP1MAPTALDH1A1KCNJ1 | |
| SCHEMBL19668622 | 0.79 | KMT2A (0.58) | POLBKMT2ATDP1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579356-B2 | Thia-tetraazaacenaphthylene kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | disclosed |
| EP-1436291-B1 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-7148215-B2 | Prodrugs as antihistamines or anticarcinogenic agents | AVENTIS PHARMA S.A. (FR) | 2006-12-12 | — | — | US | disclosed |
| WO-2006118749-A1 | THIA-TETRAAZAACENAPHTHYLENE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-11-09 | — | — | WO | disclosed |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | AVENTIS PHARMA S.A, (FR) | 2005-01-13 | — | — | US | disclosed |
| EP-1436291-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | Aventis Pharma S.A. (FR) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003024967-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2003-03-27 | — | — | WO | disclosed |
| US-4282206-A | 1-(4-AMINOPHENYL)-2-MORPHOLINYLETHANONE | WESTWOOD PHARMACEUTICALS INC. (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | POLB 2141/4885KMT2A 2686/4885TDP1 1992/4885 |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | CNKSR1, ROS1, NRAS | POLB 2885/4885KMT2A 1910/4885TDP1 1871/4885 |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | ADK, MAP3K9, MAP4K5 | POLB 2273/4885KMT2A 1521/4885TDP1 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.